New study indicates Invirase results in similar levels of viral suppression to lopinavir
14th Nov 2006, 22:41 GMT
Promising head to head results presented today indicate that the boosted protease inhibitor (PI/r) Invirase 500/r appears to achieve similar levels of viral suppression compared to the most commonly used PI, lopinavir/r, while significantly fewer patients developed elevated lipids. These results are from a planned 24 week interim analysis of 150 patients from the Gemini study presented at the HIV-8 congress in Glasgow.
New study indicates Invirase results in similar levels of viral suppression to lopinavir related news:
- Interim Analysis of New Study Suggests Boosted INVIRASE May Achieve Similar Levels of HIV Suppression to Boosted Lopinavir with a Favorable Lipid Profile — Pharmaceuticals News from StratCenter.com
- Interim Analysis Of New Study Suggests Boosted INVIRASE(R) May Achieve Similar Levels Of HIV Suppression To Boosted Lopinavir — Health News from Medical News Today
- New Study Indicates Boosted Invirase 500 Patients Achieve Similar Levels of Viral Suppression to Boosted Lopinavir but with a Better Lipid Profile — Presseportal.de Wirtschaft
- Volume 194, number 12: Treatment Benefit on Cerebrospinal Fluid HIV-1 Levels in the Setting of Systemic Virological Suppression and Failure — J Infect Dis Latest Issue
- Fatigue in women is reduced in stress-related cortisol study — EurekAlert! - Chemistry, Physics and Materials Sciences
- Volume 194, number 12: Quantification of Viral Inactivation by Photochemical Treatment with Amotosalen and UV A Light, Using a Novel Polymerase Chain Reaction Inhibition Method with Preamplification — J Infect Dis Latest Issue
- Growth-rate regulated genes have profound impact on interpretation of transcriptome profiling in Saccharomyces cerevisiae — Genome Biology - Latest articles
- VAT study to go ahead — AME Info News - Finance and Economy
- Opposites do not attract — EurekAlert! - Medicine and Health
- Volume 194, number 12: A Randomized, Partially Blinded Phase 2 Trial of Antiretroviral Therapy, HIV-Specific Immunizations, and Interleukin-2 Cycles to Promote Efficient Control of Viral Replication (ACTG A5024) — J Infect Dis Latest Issue
Latest news from EurekAlert! - Breaking News:
- Scientists capture nanoscale images with short and intense X-ray laser
- Mayo researchers offer evidence people with psoriasis greater risk for developing heart disease
- Mayo Clinic information about accelerated aging among people with rheumatoid arthritis
- ESSP launches project on the effects of global environmental change on human health
- Health inequalities are a growing problem worldwide
- HIV/AIDS linked to extensively drug resistant TB
- Higher death rate for heart attack patients with additional non-cardiac conditions
- Hormone linked to brain's cravings for food and other energy sources
- Key to acute lung injury lies in Ang2 protein
- Propane fuel cell passes muster at Exit Glacier Nature Center